BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34011306)

  • 21. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients.
    Summerer I; Unger K; Braselmann H; Schuettrumpf L; Maihoefer C; Baumeister P; Kirchner T; Niyazi M; Sage E; Specht HM; Multhoff G; Moertl S; Belka C; Zitzelsberger H
    Br J Cancer; 2015 Jun; 113(1):76-82. PubMed ID: 26057452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma.
    Hou B; Ishinaga H; Midorikawa K; Shah SA; Nakamura S; Hiraku Y; Oikawa S; Murata M; Takeuchi K
    Cancer Biol Ther; 2015; 16(7):1042-6. PubMed ID: 25950115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients.
    Yan Y; Wang X; Venø MT; Bakholdt V; Sørensen JA; Krogdahl A; Sun Z; Gao S; Kjems J
    Oncotarget; 2017 Jan; 8(5):8206-8214. PubMed ID: 28030794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two miRNA prognostic signatures of head and neck squamous cell carcinoma: A bioinformatic analysis based on the TCGA dataset.
    Wu C; Tong L; Wu C; Chen D; Chen J; Li Q; Jia F; Huang Z
    Cancer Med; 2020 Apr; 9(8):2631-2642. PubMed ID: 32064753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and Possible Molecular Mechanisms of microRNA-205-5p in Patients With Head and Neck Squamous Cell Carcinoma.
    Zhou Z; Liu C; Liu K; Lv M; Li B; Lan Z; Chen W; Kang M
    Technol Cancer Res Treat; 2020; 19():1533033820980110. PubMed ID: 33327871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.
    Trakunram K; Chaniad P; Geater SL; Keeratichananont W; Chittithavorn V; Uttayamakul S; Buya S; Raungrut P; Thongsuksai P
    Cancer Biol Med; 2020 Aug; 17(3):652-663. PubMed ID: 32944397
    [No Abstract]   [Full Text] [Related]  

  • 27. Deep sequencing-based microRNA expression signatures in head and neck squamous cell carcinoma: dual strands of pre-miR-150 as antitumor miRNAs.
    Koshizuka K; Nohata N; Hanazawa T; Kikkawa N; Arai T; Okato A; Fukumoto I; Katada K; Okamoto Y; Seki N
    Oncotarget; 2017 May; 8(18):30288-30304. PubMed ID: 28415821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated analysis of deregulation microRNA expression in head and neck squamous cell carcinoma.
    Qi CL; Sheng JF; Huang ML; Zou Y; Wang YP; Wang F; Zeng F; Hua QQ; Chen SM
    Medicine (Baltimore); 2021 Feb; 100(6):e24618. PubMed ID: 33578572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
    Shinke H; Masuda S; Togashi Y; Ikemi Y; Ozawa A; Sato T; Kim YH; Mishima M; Ichimura T; Bonventre JV; Matsubara K
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):989-96. PubMed ID: 26407820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined identification of three miRNAs in serum as effective diagnostic biomarkers for HNSCC.
    Liu C; Yu Z; Huang S; Zhao Q; Sun Z; Fletcher C; Jiang Y; Zhang D
    EBioMedicine; 2019 Dec; 50():135-143. PubMed ID: 31780396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer.
    Geng Q; Fan T; Zhang B; Wang W; Xu Y; Hu H
    Respir Res; 2014 Nov; 15(1):149. PubMed ID: 25421010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum miR-483-5p: a novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma.
    Xu H; Yang Y; Zhao H; Yang X; Luo Y; Ren Y; Liu W; Li N
    Tumour Biol; 2016 Jan; 37(1):447-53. PubMed ID: 26224475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data.
    Zhang Z; Pan B; Lv S; Ji Z; Wu Q; Lang R; He Q; Zhao X
    Cell Physiol Biochem; 2018; 49(2):678-695. PubMed ID: 30165365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miRNA profiling of primary lung and head and neck squamous cell carcinomas: Addressing a diagnostic dilemma.
    Muñoz-Largacha JA; Gower AC; Sridhar P; Deshpande A; O'Hara CJ; Yamada E; Godfrey TE; Fernando HC; Litle VR
    J Thorac Cardiovasc Surg; 2017 Aug; 154(2):714-727. PubMed ID: 28495058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.
    Niwa Y; Yamada S; Sonohara F; Kurimoto K; Hayashi M; Tashiro M; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Kodera Y
    J Transl Med; 2019 Jan; 17(1):1. PubMed ID: 30602370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients.
    Fukuda N; Yunokawa M; Fujiwara Y; Wang X; Ohmoto A; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1322. PubMed ID: 33295110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis.
    Mohamed A; Twardy B; Zordok MA; Ashraf K; Alkhoder A; Schrapp K; Steuer C; Chen Z; Pakkala S; Pillai R; Trad Wadsworth J; Higgins K; Beitler JJ; Ramalingam SS; Owonikoko TK; Khuri FR; Shin DM; Behera M; Saba NF
    Head Neck; 2019 May; 41(5):1490-1498. PubMed ID: 30835900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer.
    Saleh AD; Cheng H; Martin SE; Si H; Ormanoglu P; Carlson S; Clavijo PE; Yang X; Das R; Cornelius S; Couper J; Chepeha D; Danilova L; Harris TM; Prystowsky MB; Childs GJ; Smith RV; Robertson AG; Jones SJM; Cherniack AD; Kim SS; Rait A; Pirollo KF; Chang EH; Chen Z; Van Waes C
    Clin Cancer Res; 2019 May; 25(9):2860-2873. PubMed ID: 30723145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of miR-146a and miR-155 in blood, tissue and cell lines of head and neck squamous cell carcinoma patients and their impact on cell proliferation and migration.
    Lerner C; Wemmert S; Bochen F; Kulas P; Linxweiler M; Hasenfus A; Heinzelmann J; Leidinger P; Backes C; Meese E; Urbschat S; Schick B
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):757-66. PubMed ID: 26621153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
    McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
    Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.